• Louise S. Acheson
  • Kurt C. Stange


Osteoporosis is a condition of reduced bone density and increased susceptibility to fractures, without other recognizable causes of bone loss.1 Osteoporosis affects an estimated 15 million to 20 million people in the United States, particularly postmenopausal women and the elderly of both sexes.2 Its most common serious manifestations are fractures of the hip, forearm, and vertebrae. Measures taken at several critical periods in the life cycle, long before fractures occur, have the potential to prevent osteoporosis and its consequences. Therefore family physicians are in a key position for preventing and treating this disease.


Bone Mineral Density Bone Mass Vertebral Fracture Bone Mineral Content Estrogen Replacement Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Consensus Development Conference: prophylaxis and treatment of osteoporosis. Am J Med 1991;90:107–10.CrossRefGoogle Scholar
  2. 2.
    Consensus Conference. Osteoporosis. JAMA 1984;252:799–802.CrossRefGoogle Scholar
  3. 3.
    Marcus R. Understanding and preventing osteoporosis. Hosp Pract 1989;24:189–218.Google Scholar
  4. 4.
    Jackson JA, Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology, and prevention. Medicine (Baltimore) 1990;69: 137–52.Google Scholar
  5. 5.
    Christiansen C, editor. Proceedings of a symposium: consensus development conference on osteoporosis. Am J Med1991;91Suppl5B:lS-68S.Google Scholar
  6. 6.
    Melton LJ III, Eddy DM, Johnston CC Jr. Screening for osteoporosis. Ann Intern Med 1990;112:516–28.PubMedCrossRefGoogle Scholar
  7. 7.
    Bauer RL. Assessing osteoporosis. Hosp Pract 1991 ;26 Suppl 1:23–9.Google Scholar
  8. 8.
    Committee on Nutritional Status During Pregnancy and Lactation, Institute of Medicine, National Academy of Sciences. Nutrition during pregnancy. Washington, DC: National Academy Press, 1990:318–35.Google Scholar
  9. 9.
    Committee on Nutritional Status During Pregnancy and Lactation, Institute of Medicine, National Academy of Sciences. Nutrition during lactation. Washington, DC: National Academy Press, 1991:204–6.Google Scholar
  10. 10.
    Licata A A. Therapies for symptomatic primary osteoporosis. Geriatrics 1991;46:62–7.PubMedGoogle Scholar
  11. 11.
    Avioli LV. The osteoporotic syndrome: detection, prevention, and treatment. Orlando, FL: Grune & Stratton, 1983:30.Google Scholar
  12. 12.
    Grisso JA, Attie M. Prevention of osteoporotic fractures. In: Lav-izzo-Mourey R, Day S, Diserens D, Grisso JA, editors. Practicing prevention for the elderly. Philadelphia: Hanley & Belfus, 1989:107–23.Google Scholar
  13. 13.
    Banas MP, Kaplan FS, Fallon MD, Haddad JG. Regional migratory osteoporosis: a case report and review of the literature. Clin Orthop 1990;250:303–9.PubMedGoogle Scholar
  14. 14.
    Heidrich F, Thompson RS. Osteoporosis prevention: strategies applicable for general population groups. J Fam Pract 1987;25:33–9.PubMedGoogle Scholar
  15. 15.
    Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF. Determinants of bone density in normal women: risk factors for future osteoporosis? BMJ 1989;298:924–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Ray WA, Griffin MZ, Schaffner W, Baugh DK, Melton LJ III. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316:363–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Mezey MD, Grisso JA. Preventing dependence and injury. In: Lavizzo-Mourey R, Day S, Diserens D, Grisso JA, editors. Practicing prevention for the elderly. Philadelphia: Hanley & Belfus, 1989:125–35.Google Scholar
  18. 18.
    Patel U, Skingle S, Campbell GA, Crisp AJ, Boyle IT. Clinical profile of acute vertebral compression fractures in osteoporosis. Br J Rheumatol 1991;30:418–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Rifat SF, Kiningham RB, Peggs JF. Calcitonin in the treatment of osteoporotic bone pain. J Fam Pract 1992;35:93–6.PubMedGoogle Scholar
  20. 20.
    Slemenda CW, Hui SL, Longcope C, Wellman H, Johnston CC Jr. Predictors of bone mass in perimenopausal women: a prospective study of clinical data using photon absorptiometry. Ann Intern Med 1990;112:96–101.PubMedCrossRefGoogle Scholar
  21. 21.
    Ostlere S J, Gold RH. Osteoporosis and bone density measurement methods. Clin Orthop 1991;271:149–63.PubMedGoogle Scholar
  22. 22.
    Wasnich RD, Ross PD, Davis JW, Vogel JM. A comparison of single and multi-site BMC measurements for assessment of spine fracture probability. J Nucl Med 1989;30:1166–77.PubMedGoogle Scholar
  23. 23.
    Cummings SR, Black DM, Nevitt MC, et al. Appendicular bone density and age predict hip fracture in women. JAMA 1990;263: 665–8.PubMedCrossRefGoogle Scholar
  24. 24.
    D ATTA: diagnostic and therapeutic technology assessment: measurement of bone density with dual-energy x-ray absorptiometry (DEXA). JAMA 1992;267:286–94.CrossRefGoogle Scholar
  25. 25.
    Ross PD, Wasnich RD, MacLean C J, Hagino R, Vogel JM. A model for estimating the potential costs and savings of osteoporosis prevention strategies. Bone 1988;9:337–47.PubMedCrossRefGoogle Scholar
  26. 26.
    US Preventive Services Task Force. Estrogen prophylaxis. In: Guide to clinical preventive services. Baltimore: Williams & Wil-kins, 1989:375–9.Google Scholar
  27. 27.
    Tosteson ANA, Rosenthal DI, Melton LJ, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990;113:594–603.PubMedCrossRefGoogle Scholar
  28. 28.
    Melton LJ III, Kan SH, Wahner HW, Riggs BL. Lifetime fracture risk: an approach to hip fracture risk assessment based on bone mineral density and age. J Clin Epidemiol 1988;41:985–94.PubMedCrossRefGoogle Scholar
  29. 29.
    Cummings SR, Browner WS, Ettinger B. Should prescription of postmenopausal hormone therapy be used on the results of bone densitometry? Ann Intern Med 1990;113:565–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Byyny RL, Speroff L. A clinical guide for the care of older women. Baltimore: Williams & Wilkins, 1990:211–23.Google Scholar
  31. 31.
    Hillner BE, Hollenberg JP, Pauker SG. Postmenopausal estrogens in the prevention of osteoporosis: a benefit that is virtually without risk if cardiovascular effects are considered. Am J Med 1986;80: 1115–27.PubMedCrossRefGoogle Scholar
  32. 32.
    Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary artery disease: a quantitative review of the epidemiologic evidence. Prev Med 1991;20:47–63.PubMedCrossRefGoogle Scholar
  33. 33.
    Calcium supplements. Med Lett 1989;31:101–3.Google Scholar
  34. 34.
    Cummings SR, Rubin SM, Black D. The future of hip fractures in the United States: numbers, costs, and potential effects of postmenopausal estrogen. Clin Orthop 1990;252:163–6.PubMedGoogle Scholar
  35. 35.
    Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral content in postmenopausal women with breast cancer. N Engl J Med 1992;326:852–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Heidrich FE, Stergachis A, Gross KM. Diuretic drug use and the risk for hip fracture. Ann Intern Med 1991;115:1–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Resch H, Pietschmann P, Krexner E, Woloszczuk W, Willvonseder R. Effects of one-year hormone replacement therapy on peripheral bone mineral content in patients with osteoporotic spine fractures. Acta Endocrinol (Copenh) 1990;123:14–8.Google Scholar
  38. 38.
    Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265–71.PubMedCrossRefGoogle Scholar
  39. 39.
    Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Horowitz E, Miller JL, Rose LI. Etidronate for hypercalcemia of malignancy and osteoporosis. AmFam Physician 1991;43:2155–9.Google Scholar
  41. 41.
    Tilyard MW, Spears GFS, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357–62.PubMedCrossRefGoogle Scholar
  42. 42.
    Dequeker J, Guesens P. Treatment of established osteoporosis and rehabilitation: current practice and possibilities. Maturitas 1990;12(l):l-36.Google Scholar
  43. 43.
    Riggs BL, Hodgson SF, O’Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Pak CYC, Sakhall K, Zerwekh JE, Parcet C, Peterson R, Johnsons K. Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride; augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab 1989;68:150–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Louise S. Acheson
  • Kurt C. Stange

There are no affiliations available

Personalised recommendations